Genome Engineering allows the easy manipulation of genomes down to the nucleotide level.

Target identification in solid tumors can help enable therapeutic development against indications of high unmet need and across a wide patient population.

The SARS-CoV-2 pandemic necessitated the rapid development of high-quality monoclonal antibodies (mAbs) for therapeutic, diagnostic, and vaccine development.